• 29 Jul 2022

CatSci Investment Named as Insider’s Deal of the Month

CatSci Ltd are incredibly pleased to share that our recent significant investment by Keensight Capital has been named Insider’s Deal of the Month.
  • News

CatSci Ltd are incredibly pleased to share that our recent significant investment by Keensight Capital has been named Insider’s Deal of the Month for June.

Keensight Capital is one of the leading private equity managers dedicated to pan-European Growth Buyout investments.

Keensight Capital are investing behind CatSci management to support continued growth of the core business via capability and site expansion, as well as the development of GMP capabilities and the expansion of its offering in oligonucleotide services. Keensight Capital will bring its expertise and successful track record of investments in the CRDMO (Contract Development and Manufacturing Organisation) space, with the ability to help accelerate growth through accretive M&A. This will enable CatSci to continue offering “more and better” to its customers in order to deliver best-in-class medicines for patients worldwide.

We were advised by corporate finance advisory firm, Shaw & Co, throughout the investment process.

Read more here.

Resources & Insights

  • 8 Dec 2025
  • Alison Gordon, Kathy Dodgson, Ryan Mordue, Tom Miller, Vesna Vetma O'Leary
PROductive TACtics Streamlined, multifaceted approaches to unlocking PROTAC® screening insights
  • Bioscience
  • Case Studies
489 KB
  • 2 Dec 2025
CatSci x BRAINBiocatalysts Conference 2026
  • Events
  • 2 Dec 2025
2nd Innovations in Peptide Science 2026
  • Events
  • 28 Nov 2025
Advances in Small Molecule Drug Development, Boston 2026
  • Events